FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203613325> ?p ?o ?g. }

• W3203613325 abstract "Background: Locally advanced pancreatic cancer (LAPC) has a dismal prognosis with current treatment modalities and one-third of patients die from local progression of disease. Preclinical studies with orthotopic PC demonstrated dramatic synergy between radiotherapy (RT) and the poly(ADP-ribose) polymerase-1/2 inhibitor (PARPi), veliparib. We conducted a phase I trial of gemcitabine, radiotherapy and dose-escalated veliparib in LAPC. Methods: This was a single institution investigator-initiated open-label, single-arm phase 1 clinical trial (NCT01908478). Weekly gemcitabine with daily IMRT and veliparib dose escalated using a Bayesian adaptive design were administered in treatment naive LA or borderline resectable PC. The primary end point was identification of the MTD. Secondary endpoints included efficacy, characterization of PAR levels using ELISA, DDR alterations with targeted next generation sequencing and transcriptome analysis, tumor mutation burden (TMB) and microsatellite instability (MSI) status. Findings: Thirty patients were enrolled. The MTD of veliparib was 40 mg BID with gemcitabine 400 mg/m2 and RT (36 Gy/15 fractions). Sixteen DLTs were identified in 12 patients. Grade ≥ 3 adverse events included lymphopenia (96%) and anemia (36%). Median OS for all patients was 15 months. Median OS for DDR pathway gene altered and intact cases was 19 months (95% CI: 6.2-27.2) and 14 months (95% CI: 10.0-21.8), respectively. There were no significant associations between levels of PAR, TMB, or MSI with outcomes. The DDR transcripts PARP3 and RBX1 significantly correlated with OS.  Interpretation: This is the first report of a PARPi-chemoradiotherapy combination in PC. The regimen was safe, tolerable at the RP2D, and clinically active as an upfront treatment strategy in patients biologically unselected by upfront chemotherapy. Expression of the DDR transcripts, PARP3 and RBX1, were associated with OS suggesting validation in a follow up phase 2 study.Clinical Trial Number:  (NCT01908478) Funding Statement: Phase One Foundation; National Institutes of Health [1R01CA188480-01A1, P01 CA098912]. Veliparib was provided by Abbvie. Declaration of Interests: RT has served as an advisor for Astra Zeneca. SJK has served as a consultant/advisor for Lilly Oncology, Astellas, and Boston Biomedical, and is on the speaker bureau for Foundation Medicine, Inc. All remaining authors have declared no conflicts of interest.Ethics Approval Statement:  The authors state that the study is institutional review board approved." @default.
• W3203613325 created "2021-10-11" @default.
• W3203613325 creator A5000002459 @default.
• W3203613325 creator A5004103417 @default.
• W3203613325 creator A5004343685 @default.
• W3203613325 creator A5005658250 @default.
• W3203613325 creator A5014710892 @default.
• W3203613325 creator A5021340201 @default.
• W3203613325 creator A5024750927 @default.
• W3203613325 creator A5024986804 @default.
• W3203613325 creator A5027630636 @default.
• W3203613325 creator A5030029427 @default.
• W3203613325 creator A5030308961 @default.
• W3203613325 creator A5031352775 @default.
• W3203613325 creator A5034066139 @default.
• W3203613325 creator A5045162411 @default.
• W3203613325 creator A5061146434 @default.
• W3203613325 creator A5061329283 @default.
• W3203613325 creator A5063273969 @default.
• W3203613325 creator A5063600668 @default.
• W3203613325 creator A5071611972 @default.
• W3203613325 creator A5075496173 @default.
• W3203613325 creator A5087391729 @default.
• W3203613325 date "2018-12-19" @default.
• W3203613325 modified "2023-10-14" @default.
• W3203613325 title "First-in-Human Phase 1 Study of Veliparib, a PARP-1/2 Inhibitor, with Gemcitabine and Radiotherapy in Locally Advanced Pancreatic Cancer" @default.
• W3203613325 hasPublicationYear "2018" @default.
• W3203613325 type Work @default.
• W3203613325 sameAs 3203613325 @default.
• W3203613325 citedByCount "0" @default.
• W3203613325 crossrefType "posted-content" @default.
• W3203613325 hasAuthorship W3203613325A5000002459 @default.
• W3203613325 hasAuthorship W3203613325A5004103417 @default.
• W3203613325 hasAuthorship W3203613325A5004343685 @default.
• W3203613325 hasAuthorship W3203613325A5005658250 @default.
• W3203613325 hasAuthorship W3203613325A5014710892 @default.
• W3203613325 hasAuthorship W3203613325A5021340201 @default.
• W3203613325 hasAuthorship W3203613325A5024750927 @default.
• W3203613325 hasAuthorship W3203613325A5024986804 @default.
• W3203613325 hasAuthorship W3203613325A5027630636 @default.
• W3203613325 hasAuthorship W3203613325A5030029427 @default.
• W3203613325 hasAuthorship W3203613325A5030308961 @default.
• W3203613325 hasAuthorship W3203613325A5031352775 @default.
• W3203613325 hasAuthorship W3203613325A5034066139 @default.
• W3203613325 hasAuthorship W3203613325A5045162411 @default.
• W3203613325 hasAuthorship W3203613325A5061146434 @default.
• W3203613325 hasAuthorship W3203613325A5061329283 @default.
• W3203613325 hasAuthorship W3203613325A5063273969 @default.
• W3203613325 hasAuthorship W3203613325A5063600668 @default.
• W3203613325 hasAuthorship W3203613325A5071611972 @default.
• W3203613325 hasAuthorship W3203613325A5075496173 @default.
• W3203613325 hasAuthorship W3203613325A5087391729 @default.
• W3203613325 hasConcept C104317684 @default.
• W3203613325 hasConcept C121608353 @default.
• W3203613325 hasConcept C126322002 @default.
• W3203613325 hasConcept C143998085 @default.
• W3203613325 hasConcept C182979987 @default.
• W3203613325 hasConcept C203092338 @default.
• W3203613325 hasConcept C2778424827 @default.
• W3203613325 hasConcept C2779138821 @default.
• W3203613325 hasConcept C2779962180 @default.
• W3203613325 hasConcept C2780210213 @default.
• W3203613325 hasConcept C2780258809 @default.
• W3203613325 hasConcept C2781312401 @default.
• W3203613325 hasConcept C31760486 @default.
• W3203613325 hasConcept C509974204 @default.
• W3203613325 hasConcept C535046627 @default.
• W3203613325 hasConcept C55493867 @default.
• W3203613325 hasConcept C71924100 @default.
• W3203613325 hasConcept C82381507 @default.
• W3203613325 hasConcept C86803240 @default.
• W3203613325 hasConceptScore W3203613325C104317684 @default.
• W3203613325 hasConceptScore W3203613325C121608353 @default.
• W3203613325 hasConceptScore W3203613325C126322002 @default.
• W3203613325 hasConceptScore W3203613325C143998085 @default.
• W3203613325 hasConceptScore W3203613325C182979987 @default.
• W3203613325 hasConceptScore W3203613325C203092338 @default.
• W3203613325 hasConceptScore W3203613325C2778424827 @default.
• W3203613325 hasConceptScore W3203613325C2779138821 @default.
• W3203613325 hasConceptScore W3203613325C2779962180 @default.
• W3203613325 hasConceptScore W3203613325C2780210213 @default.
• W3203613325 hasConceptScore W3203613325C2780258809 @default.
• W3203613325 hasConceptScore W3203613325C2781312401 @default.
• W3203613325 hasConceptScore W3203613325C31760486 @default.
• W3203613325 hasConceptScore W3203613325C509974204 @default.
• W3203613325 hasConceptScore W3203613325C535046627 @default.
• W3203613325 hasConceptScore W3203613325C55493867 @default.
• W3203613325 hasConceptScore W3203613325C71924100 @default.
• W3203613325 hasConceptScore W3203613325C82381507 @default.
• W3203613325 hasConceptScore W3203613325C86803240 @default.
• W3203613325 hasLocation W32036133251 @default.
• W3203613325 hasOpenAccess W3203613325 @default.
• W3203613325 hasPrimaryLocation W32036133251 @default.
• W3203613325 isParatext "false" @default.
• W3203613325 isRetracted "false" @default.
• W3203613325 magId "3203613325" @default.
• W3203613325 workType "article" @default.